Royalty Pharma (RPRX) Dividends Paid - Common (2019 - 2026)

Royalty Pharma has disclosed Dividends Paid - Common across 8 years of filings, most recently posting $39.9 million for Q1 2026.

• Dividends Paid - Common for Q1 2026 came in at $39.9 million, down 25.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.5 million (up 4.45% YoY), and the FY2025 annual result was $167.5 million, up 33.81% from the prior year.
• Dividends Paid - Common came in at $39.9 million for Q1 2026 at Royalty Pharma, down from $40.8 million in the prior quarter.
• In the past five years, Dividends Paid - Common ranged from a high of $53.8 million in Q1 2025 to a low of $24.5 million in Q4 2023.
• The 5-year median for Dividends Paid - Common is $33.4 million (2023), against an average of $35.1 million.
• Peak annual rise in Dividends Paid - Common reached 114.4% in 2022, while the deepest fall reached 72.55% in 2022.
• Royalty Pharma's Dividends Paid - Common stood at $33.2 million in 2022, then declined by 26.13% to $24.5 million in 2023, then grew by 28.42% to $31.4 million in 2024, then increased by 29.6% to $40.8 million in 2025, then retreated by 2.15% to $39.9 million in 2026.
• The last three Dividends Paid - Common figures came in at $39.9 million (Q1 2026), $40.8 million (Q4 2025), and $34.3 million (Q3 2025), per Business Quant data.